Kotaka, Masahito http://orcid.org/0000-0001-5976-613X
Iwamoto, Shigeyoshi
Satake, Hironaga
Sakai, Daisuke
Kudo, Toshihiro
Fukunaga, Mutsumi
Konishi, Ken
Ide, Yoshihito
Ikumoto, Taro
Tsuji, Akihito
Sano, Yasushi
Kato, Takeshi
Sugimoto, Naotoshi
Satoh, Taroh
Kanazawa, Akiyoshi
Kurata, Takayasu
Yamanaka, Takeharu
Tomita, Naohiro
Funding for this research was provided by:
Surgeons and Oncologists study group for developing New strategy In Cancer treatment
Article History
Received: 17 February 2020
Accepted: 30 April 2020
First Online: 14 May 2020
Compliance with ethical standards
:
: M. Kotaka has received honoraria from Chugai Pharma and Yakult Honsha. S. Iwamoto and H. Satake have received honoraria from Chugai Pharma. D. Sakai has received honoraria and research funding from Chugai Pharma; research funding from Yakult Honsha. T. Kudo belong to a donated fund laboratory from Yakult Honsha, Chugai Pharma, and Ono Pharma. A. Tsuji has received honoraria from Chugai Pharma; research funding from Kyowa Kirin. N. Sugimoto has received research funding from Chugai Pharma. T. Satoh has received honoraria from Yakult Honsha; belonging to a donated fund laboratory from Yakult Honsha and Chugai Pharma. T. Yamanaka has received honoraria and research funding from Takeda Pharma, Chugai Pharma, Boehringer Ingelheim, Taiho pharma, Daiichi-Sankyo, and Ono Pharma; research funding from Merck Biopharma, Astellas Pharma, and Bayer. N. Tomita has received research funding from Chugai Pharma, Eli Lilly Japan, Taiho pharma, Beyer. and Sysmex. All remaining authors indicated no potential conflict of interest.